Abstract: Transient receptor potential ankyrin 1 (TRPA1) is a non⁃selective cation channel receptor that is extensively distributed in sensory neurons and the tumor microenvironment. TRPA1 is involved in the transduction and regulation of pain signals through both pathological and physiological mechanisms， including the detection of inflammatory mediators， oxidative stress products， and the release of neuropeptides. This makes TRPA1 a promising therapeutic target for cancer⁃related pain. TRPA1 antagonists have been shown to effectively alleviate mechanical hyperalgesia and cold allodynia in animal models. Additionally， natural products and gene therapy technologies targeting TRPA1 demonstrate potential for pain management. Nonetheless， the clinical translation of TRPA1⁃targeted therapies remains challenging due to the biological characteristics inherent to the target， the complexity of the tumor microenvironment， and technical bottlenecks in the clinical translation process. This review summarizes the molecular characteristics and interactive regulatory networks of TRPA1， elucidates its pathophysiological mechanisms in cancer⁃related pain， and discusses advancements in preclinical research alongside prospects for translational medicine， with the objective of offering valuable ideas for the management of cancer⁃related pain.

Key words: Transient receptor potential ankyrin 1, Cancer?related pain, Tumor microenvironment, Antagonist, Clinical translation